jump to navigation

Lisa Warren Examines the Value of In-Person Interviews for Expediting Patent Allowance in Mass. Lawyers Weekly Article 08/15/2017

Posted by Morse Barnes-Brown Pendleton in Attorney News, Life Sciences, Intellectual Property.
Tags: , , , ,
add a comment

LMW Headshot Photo 2015 (M0846622xB1386)In her Massachusetts Lawyers Weekly article “Expediting Patent Allowance with In-Person Interviews,” patent attorney Lisa Warren explains why it may be beneficial to take advantage of in-person interviews with the U.S. Patent & Trademark Office in order to expedite the allowance of a patent. Although options such as telephone or video conference interviews may be available and more convenient, Lisa notes:

sometimes there is simply no substitute for direct interpersonal interaction with an examiner to build rapport and improve the mutual understanding of the issues.”

Additionally, Lisa addresses relevant considerations when deciding if in-person interviews are preferable during the patent application process, as well as requirements for the interview itself. These and other insights from Lisa can be found in the full article.

Lisa McKerracher of BioAxone BioSciences Joins Advisory Panel for Christopher Reeve Foundation 08/10/2017

Posted by Morse Barnes-Brown Pendleton in Client News, Life Sciences.
Tags: , , ,
add a comment

Lisa McKerracher, CEO of MBBP client BioAxone BioSciences, has accepted the role of Consortium Advisory Panelist for the Christopher & Dana Reeve Foundation. Dr. McKerracher will “direct the foundation’s focus toward the identification, development, and translation of potential Spinal Cord Injury (SCI) therapies into the clinic.”

BioAxone BioSciences is a clinical-state biopharmaceutical company developing regenerative therapeutic drugs based on a deep understanding of axon regeneration and neuronal signaling pathways. The Christopher & Dana Reeve Foundation is dedicated to advancing quality of life and discovering cures for spinal cord injury.

More information can be found in the full release.

David Sabatini To Be Awarded 2017 Dickson Prize in Medicine 08/10/2017

Posted by Morse Barnes-Brown Pendleton in Client News, Life Sciences.
Tags: , , ,
add a comment

whitehead-institute-client-logo-sm-m0055040xb1386Biologist David Sabatini of MBBP client Whitehead Institute will receive the University of Pittsburgh’s 2017 Dickson Prize in Medicine. The Dickson Prize in Medicine is awarded annually to a leading American investigator who is engaged in innovative, paradigm-shifting biomedical research.

Sabatini discovered mTOR, a key cellular regulatory metabolic pathway. In addition to being a member of the Whitehead Institute for Biomedical Research, he teaches biology at MIT and is a senior associate at the Broad Institute of MIT and Harvard University. He is also a member of the MIT Koch Institute for Integrative Cancer Research and is a Howard Hughes Medical Institute investigator.

The award will be presented to Sabatini in October at the University of Pittsburgh’s Science 2017 event. More information can be found on the University’s Dickson Prize in Medicine page.

Bach Pharma’s GVT Drug Reverses Brain Dysfunction, Report Shows 08/09/2017

Posted by Morse Barnes-Brown Pendleton in Client News, Life Sciences.
Tags: , , , ,
add a comment

Firm client Bach Pharma’s GVT drug successfully reverses brain dysfunction and therefore may be an effective treatment for victims of Gulf War Illness (GWI), according to a Department of Defense report on the results of a multi-year pre-clinical study conducted by Ashok K. Shetty, PhD, Associate Director and Professor at the Institute for Regenerative Medicine at the College of Medicine at Texas A&M University System. GWI is prevalent among servicemen and women from the Gulf War and can cause memory impairment, depression, and anxiety. The study was conducted under a grant from the DoD.

GVT has proven both neuro-protective and neuro-generative and could potentially act as a therapeutic treatment for chemical poisoning associated disorders. The fact that GVT regenerates stem cells and neurons was an unexpected finding of this study. Based on these results, Dr. Shetty has established a collaboration with Dena Davidson, PhD, deputy director of research at the Veterans Integrated Service Network (VISN) 17 Center of Excellence for Research on Returning War Veterans to pursue clinical trials in GWI patients.

Congratulations to our client, Bach Pharma, on this extraordinary achievement. Read the full press release for more information.

Mike Jabbawy Participating on Shoobx Startup Panel 08/08/2017

Posted by Morse Barnes-Brown Pendleton in Attorney News, Corporate, Events, Venture Capital & Private Equity.
Tags: , , ,
add a comment

MRJ Headshot Photo 2017 (M1047116xB1386)On September 26, corporate partner Mike Jabbawy will take part in the panel “How to Start a Startup”. The panel is part of Shoobx’s Startup Series, which features real life stories from startup founders, investors, and community members. Items of discussion will include choosing a form of entity for a business, choosing co-founders, and how to find assistance to get your business off the ground.

For more information, including registration details, visit our VCs and Startups blog.

NIH/SBIR Grant Awarded to Firm Client BioAxone BioSciences for BA-1049 Inhibitor Research 08/03/2017

Posted by Morse Barnes-Brown Pendleton in Client News, Life Sciences.
Tags: , ,
add a comment

The National Institutes of Health (NIH), Small Business Innovation Research (SBIR), and National Institute of Neurological Disorders and Stroke have awarded firm client BioAxone BioSciences, Inc. with a $1.5 million grant. The grant is for continued research for BioAxone’s Rho Kinase 2 (ROCK2) inhibitor, BA-1049, a transformative drug to treat cerebral cavernous malformation, a serious genetic disease.

BioAxone is a clinical-state biopharmaceutical company developing regenerative therapeutic drugs based on a deep understanding of axon regeneration and neuronal signaling pathways.

Congratulations to our client on receiving the grant and on their revolutionary drug research. For more information, read the full release.

Firm Clients Sheprd and iZotope Are Finalists in MassTLC Leadership Awards 07/27/2017

Posted by Morse Barnes-Brown Pendleton in Client News, Computer Software & Hardware, Internet and E-Commerce, Telecommunications & Networking.
Tags: , , ,
add a comment

Firm clients Sheprd and iZotope are among the 2017 MassTLC Technology Leadership Awards finalists. The awards, presented by the Mass Technology Leadership Council, are comprised of individual and company categories, including CEO of the Year, Emerging Executive of the Year, Emerging Company of the Year, Cutting Edge Technology of the Year, and Technology for a Better Tomorrow, among others.

Sheprd and iZotope are both finalists in the Innovative Tech of the Year: Consumer category. The winners will be announced at the MassTLC Leadership Awards Gala on September 14th.

Congratulations and good luck to our clients, Sheprd and iZotope.

Scott Bleier Moderating ABA Venture Capital Webinar This Thursday 07/24/2017

Posted by Morse Barnes-Brown Pendleton in Attorney News, Corporate, Events, Venture Capital & Private Equity.
Tags: , , ,
add a comment

M0846500This Thursday, July 27th, beginning at 1pm EST, corporate attorney Scott Bleier will moderate the ABA Business Law Section webinar “Roadmap of a Venture Capital Deal“. The panel will cover various topics of the lifecycle of a venture capital financing transaction.

Visit our VCs and Startups blog for more information about the webinar and details on how to register.

BioAxone BioSciences Peer-Reviewed Research Article Published in Frontiers Journal Series 07/20/2017

Posted by Morse Barnes-Brown Pendleton in Client News, Life Sciences.
Tags: , ,
add a comment

Firm client BioAxone BioSciences announced that its peer-reviewed research article on axon regeneration was published in Frontiers Journal Series, Frontiers in Molecular Neuroscience. The article “MAG, Myelin and Overcoming Growth Inhibition in the CNS” was written by BioAxone’s CEO Lisa McKerracher, Ph.D. and Kenneth Rosen, Ph.D., VP of Research. Frontiers in Molecular Neuroscience publishes rigorously peer-reviewed research that aims to identify key molecules underlying the structure, design, and function of the brain across all levels.

BioAxone is a clinical-state biopharmaceutical company developing regenerative therapeutic drugs based on a deep understanding of axon regeneration and neuronal signaling pathways.

Congratulations to our client on this achievement. For more information, read the press release.

Chip Wry Discusses Planning for Tax Reform in Accounting Today Article 07/05/2017

Posted by Morse Barnes-Brown Pendleton in Attorney News, Financial Services, Taxation.
Tags: , ,
add a comment

M0846619Accounting Today’s article “Getting Ahead of Tax Reform” discusses the importance of planning and action for businesses before the potential tax reform takes place. Tax attorney Chip Wry comments on the uncertainty of which pieces of the proposed legislation will be enacted, and notes the possible implications regarding the elimination of the interest expense deduction and the expensing of capital expenditures. Chip also discusses how tax reform could affect choice of entity for new businesses, particularly the choice between C corporation or LLC. Chip notes:

Before the individual rates went up under the current rules, we formed a higher percentage of companies as LLCs than after they increased… But with the increase in rates, we were more willing to form companies as a C corporation.”

For more of Chip’s insights into potential tax reform, read the full Accounting Today article.

ConforMIS Receives FDA Clearance for iTotal Hip Replacement System 06/27/2017

Posted by Morse Barnes-Brown Pendleton in Client News, Life Sciences, Medical Devices.
Tags: ,
add a comment

conformis-inc-logoFirm client ConforMIS, Inc. received FDA 510(k) clearance for its primary iTotal Hip replacement system. Chief Executive Officer and President Mark Augusti remarked:

Having treated over 50,000 patients with customized knee replacement implants, ConforMIS brings over a decade of experience in patient-specific technology to the hip replacement market. FDA clearance of iTotal Hip demonstrates the ability to apply our proprietary iFit® image-to-implant technology to other joints. There has been a trend towards personalized healthcare and we believe patients expect and deserve personalized treatment.”

The iTotal Hip replacement system has technology that is similar to that used in ConforMIS’s customized knee implants. The company hopes to improve patient outcomes through customized implants for joint replacements.

Congratulations to our client on this achievement. For more information, read the full announcement.

The Risks of Using Finders and Unregistered Brokers 06/21/2017

Posted by Morse Barnes-Brown Pendleton in Attorney News, Corporate, Financial Services, Private Investment Funds & Advisers.
Tags: , , , ,
add a comment

JHW Headshot Photo 2016 (M0990045xB1386)Private fund managers often use placement agents, finders, and other intermediaries to help raise capital for their investment funds. Using an intermediary that has failed to register as a broker-dealer, however, is fraught with risk. In his article “The Risks of Using Finders and Unregistered Brokers”, private funds attorney Josh Watson cautions against using unregistered brokers and describes how to determine when an intermediary should be registered.

Read the full article on our website. For more information, please contact Josh Watson or a member of our PIFA practice.

iSpecimen Unveils Online Biospecimen Marketplace 06/13/2017

Posted by Morse Barnes-Brown Pendleton in Client News, Life Sciences.
Tags: , ,
add a comment

iSpecimen Logo (M0910032xB1386)Firm client iSpecimen has launched an online biospecimen marketplace for the life sciences industry. The company hopes that the marketplace will alleviate scientists’ difficulty in finding high-quality samples of human material necessary to conduct research.

The marketplace compiles available samples and allows users to search by patient information. Users can then order the corresponding materials.

For more information about the iSpecimen Marketplace, read the full article in the BBJ, or iSpecimen’s press release.

Registration Exemptions for Investment Advisers 06/08/2017

Posted by Morse Barnes-Brown Pendleton in Attorney News, Corporate, Financial Services, MBBP news, Private Investment Funds & Advisers, Venture Capital & Private Equity.
Tags: , , , , ,
add a comment

JHW Headshot Photo 2016 (M0990045xB1386)When may an investment adviser avoid registering with the Securities and Exchange Commission? Private funds attorney Josh Watson answers this question in his article “Registration Exemptions for Investment Advisers” that summarizes the requirements of two registration exemptions that are available to managers of private investment funds.

To learn about the two registration exemptions read the full article on our website. For more information, please contact Josh Watson or a member of our PIFA practice.

Encore Event! Strategic Alliances: Pot of Gold or Pretty Poison? – Life Sciences Series, June 28 06/05/2017

Posted by Morse Barnes-Brown Pendleton in Attorney News, Corporate, Events, Life Sciences, MBBP news.
Tags: , , , ,
add a comment

JMH Headshot Photo 2015 (M0846571xB1386)Due to overwhelming demand for our April 28 “Strategic Alliances: Pot of Gold or Pretty Poison?” event, we will be holding another round on Wednesday, June 28 at the Cambridge Innovation Center (CIC). Moderated by corporate attorney John Hession, a panel of business development experts will explore various research and collaboration structures, from options to license to comprehensive collaboration partnerships. The panel will discuss various licensing vehicles, the importance of concise fields of use descriptions, sample economics, and conventional transaction structures.

Space is limited! View our event page for more information and to register for the event.

Shann Kerner Joins MBBP as Intellectual Property Partner 05/03/2017

Posted by Morse Barnes-Brown Pendleton in Attorney News, Intellectual Property, Life Sciences, MBBP news.
Tags: , , ,
add a comment

SLK Headshot Photo 2017 (M1062434xB1386)We are pleased to announce the addition of Intellectual Property Member Shann Kerner.

Shann has substantial experience advising emerging, mid-sized and public companies in the biotechnology, pharmaceutical and medical device fields, counseling them on the creation, leveraging and protection of IP, with a view towards strengthening the business strategy of her clients.

A versatile and seasoned member of the Intellectual Property department, Shann concentrates her practice on IP counseling, particularly on patent portfolio procurement and management and IP due diligence in connection with venture capital, mergers and acquisitions, IPOs, and internal audits. Shann also focuses on analyses regarding patentability, freedom-to-operate, inventorship, derivation, validity and competitive subject matter landscape.

We invite you to contact Shann directly.

Tales from the Trenches: Reflections on Successful Exits – Venture Capital Event, May 18 04/28/2017

Posted by Morse Barnes-Brown Pendleton in Attorney News, Corporate, Events, MBBP news, Venture Capital & Private Equity.
Tags: , , , ,
add a comment

M0846500Our Venture Capital team will be hosting a panel event, Tales from the Trenches: Reflections on Successful Exits, on Thursday May 18 at the Cambridge Innovation Center (CIC). Moderated by corporate partner Scott Bleier, a panel of entrepreneurs will share stories about how they built and eventually sold their companies to large strategic acquirers.

Space is limited! View our VCs and Startups blog for more information, including how to register.

Applied BioMath and Northern Biologics to Collaborate on Biotherapeutic Candidate in Oncology 04/21/2017

Posted by Morse Barnes-Brown Pendleton in Client News, Life Sciences.
Tags: , ,
add a comment

Applied BioMath logo (M1064209xB1386)Firm client Applied BioMath, the industry-leader in applying mechanistic modeling to drug research and development, announced a collaboration with Northern Biologics, an innovative antibody discovery and development company. The companies will focus on traditional and mechanistic pharmacokinetic and pharmacodynamics (PK/PD) modeling for a biotherapeutic candidate in oncology. Applied BioMath will leverage both traditional PK/PD models and semi-mechanistic PK/PD models, while Northern Biologics will use this model to strengthen their understanding of the parameters that will determine optimal dosing paradigms.

Congratulations to our client on this new collaboration. For more information, read the full press release.

MBBP’s Life Sciences Vector Newsletter, Spring 2017 04/20/2017

Posted by Morse Barnes-Brown Pendleton in Attorney News, Corporate, Intellectual Property, Life Sciences, MBBP news, New Resources.
Tags: ,
add a comment

ext

Our Life Sciences team has published the Spring 2017 edition of its newsletter, Vector. Below you will find brief descriptions of the news and articles included in the publication. Read the full newsletter for more information.

DAVID CZARNECKI AND STANLEY CHALVIRE ELEVATED WITHIN THE FIRM

We are pleased to announce that David Czarnecki and Stanley Chalvire have been elevated to Member. Dave is exceptionally proficient in guiding both buyers and sellers through a wide range of corporate transactions. Stan is a Registered Patent Attorney, specializing in the licensing of intellectual property and related counseling.

AMANDA PHILLIPS NAMED 2017 UP & COMING LAWYER

Litigation associate Amanda Phillips has been named a 2017 Up & Coming Lawyer by Massachusetts Lawyers Weekly. The recognition is awarded to a select number of attorneys who have been practicing for fewer than 10 years but whose professional achievements are noteworthy and whose service to the community is also significant.

CORPORATE ATTORNEY MICHAEL JABBAWY JOINS FIRM AS PARTNER

Michael’s practice is focused primarily in the areas of emerging and growth technology companies, venture capital, M&A transactions, and corporate governance. As a member of the Corporate Department, Michael advises technology and other emerging companies through each stage of growth. Prior to joining MBBP, Michael was a member of the Technology Companies group at Goodwin Procter LLP.

RECENT LIFE SCIENCES TRANSACTIONS

MBBP represented several clients in life sciences transactions, including iSpecimen, Orionis Biosciences, First Light Biosciences, and Manus Biosynthesis. The transactions ranged from convertible debt to equity investments. Learn more on page 2.

FREEDOM TO OPERATE: PREVENTION IS THE BEST MEDICINE

Launching a new product or service can be fraught with uncertainty and involve large expenditures of limited resources. An FTO opinion can reduce uncertainty and provide some insurance against loss from an unfavorable finding of infringement of another’s patent. An FTO opinion makes a determination whether a product or service infringes issued patents. In other words, the opinion indicates whether or not there is “freedom to operate” the product or service within the patent landscape. Often, FTO opinions also identify patent applications that, if later issued as patents, may be problematic. Read the full article on page 2.

THE PATENT PROCESS: GET ON THE FAST TRACK

One of the biggest frustrations for patent applicants is the incredibly slow pace at which an application proceeds from filing to receipt of a substantive examination report to allowance. On average it takes 15.7 months for a patent application to receive even a first substantive examination report, though there is significant variability across technology areas. The Patent Office has recognized this problem and implemented several initiatives which attempt to address the problem from different angles. Two programs in particular have gained traction: the Patent Prosecution Highway (PPH) and Track One Prioritized Examination. Continue reading for more information about these programs.

OWNERSHIP OF ARISING INVENTIONS IN JOINT DEVELOPMENT AGREEMENTS

Collaboration remains a valuable means of fostering innovation and advancing scientific, clinical and commercial objectives. Towards that end, two or more parties contemplating a collaboration often consider entering into a Joint Development Agreement, where they define, among other things, their respective contributions and responsibilities towards their common objectives. These types of collaborations require a careful and thorough consideration of the disposition of intellectual property rights that may arise as a result of each party’s performance of its responsibilities under such collaborations. Read more starting on page 3.

GUEST COLUMN:
FOR SKILLED IMMIGRATION TO THE U.S., THE TIMES, THEY MAY BE CHANGING

The last year of the Obama Administration saw an increased activism by President Obama in the area of skilled immigration. Through Executive Orders and regulations, the President made a number of important changes including providing Employment Authorization for spouses on H-4 visas, increasing the period of post-graduate employment authorization for foreign students in STEM fields (Science, Technology, Engineering and Mathematics), increasing the number of academic fields included in STEM and formalizing a grace period for foreign nationals on H-1B visas that find themselves between jobs. Read the full article beginning on page 5.

WatchRx Selected as Top Innovator by AARP and MedCity News 04/19/2017

Posted by Morse Barnes-Brown Pendleton in Client News, Medical Devices, Telecommunications & Networking.
Tags: , , ,
add a comment

WatchRx Logo (M0897830xB1386)Jayanthi Narasimhan, Founder and CEO of firm client WatchRx, has been named a 50+ Innovation Leader by AARP and MedCity News. The honor recognizes the leading innovators of services and products designed to serve the booming 50+ consumer health market.

Those who made the list were selected by their peers by voting. Modernizing patient care to meet the needs of today’s mobile world was a common goal of many of the winners, as well as exceptional creativity in alternative therapies, smart wearables, and product design.

WatchRx was founded from the need of the founders’ to assist their aging parents with managing medications and health conditions remotely for their multiple chronic conditions. The company delivers global award winning products to consumer, telecommunications, and enterprise industries.

Congratulations to all of the winners and to our client, Jayanthi of WatchRx!

%d bloggers like this: